B cells, also known as classical immune cells in the TME, are gradually being recognized as closely related to the response rate to PD-1 therapy [19, 20], even exceeding the scope explained by tumour-infiltrating T cells (TIL-T cells). The gene discussed is PDCD1; the disease is neoplasm.